CCAAT/enhancer binding protein delta (C/EBPδ) deficiency does not affect bleomycin-induced pulmonary fibrosis
Background: Idiopathic pulmonary fibrosis is a devastating fibrotic diffuse parenchymal lung disorder that remains refractory to pharmacological therapies. Therefore, novel treatments are urgently required. CCAAT/enhancer binding protein delta (C/EBPδ) is a transcription factor that mediates critical cellular functions in pathophysiology and which was recently suggested to be a key regulatory component in IPF. The purpose of this study was to prove or refute the importance of C/EBPδ in pulmonary fibrosis.
Methods: Pulmonary fibrosis was induced by intranasal instillation of bleomycin into wild-type and C/EBPδ deficient mice. At different time intervals after bleomycin instillation, fibrosis was assessed by hydroxyproline analysis, histochemistry and q-PCR for fibrotic marker expression.
Results: C/EBPδ deficient mice developed pulmonary fibrosis to a similar degree as wildtype mice as evident from similar Ashcroft scores, hydroxyproline levels and expression levels of collagen, fibronectin and α-smooth muscle actin at both 14 and 21 days after bleomycin instillation. The resolution of fibrosis, assessed at 48 days after bleomycin instillation, was also similar in wildtype and C/EBPδ deficient mice. In line with the lack of effect of C/EBPδ on fibrosis progression/resolution, macrophage recruitment and/or differentiation were also not different in wildtype or C/EBPδ deficient mice.
Conclusions: Overall, C/EBPδ does not seem to affect bleomycin-induced experimental pulmonary fibrosis and we challenge the importance of C/EBPδ in pulmonary fibrosis.
Relevance for patients: This study shows that the transcription factor C/EBPδ does not play a major role in the development of pulmonary fibrosis. Pharmacological targeting of C/EBPδ is therefore not likely to have a beneficial effect for patients suffering from pulmonary fibrosis.
[1] King TE Jr, Pardo A, Selman M, et al. Idiopathic Pulmonary Fibrosis. Lancet 2011; 378: 1949-61.
[2] Gross TJ, Hunninghake GW. Idiopathic Pulmonary Fibrosis. N Engl J Med 2001; 345: 517-25.
[3] du Bois RM. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 2010; 9: 129-40.
[4] Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-82.
[5] King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-92.
[6] Wuyts WA, Antoniou KM, Borensztajn K, et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir Med 2014; 2: 933-42.
[7] Lekstrom-Himes J, Xanthopoulos KG. Biological role of the CCAAT/enhancer-binding protein family of transcription factors.J Biol Chem 1998; 273: 28545-8.
[8] Juan TS, Wilson DR, Wilde MD, Darlington GJ. Participation of the transcription factor C/EBP delta in the acute-phase regulation of the human gene for complement component C3. Proc Natl Acad Sci USA 1993; 90: 2584-8.
[9] Balamurugan K, Sterneck E. The many faces of C/EBPδ and their relevance for inflammation and cancer. Int J Biol Sci 2013; 9: 917 33
[10] Gangwar I, Kumar Sharma N, Panzade G, et al. Detecting the Molecular System Signatures of Idiopathic Pulmonary Fibrosis through Integrated Genomic Analysis. Sci Rep 2017; 7: 1554.
[11] Duitman J, Hoogendijk AJ, Groot AP, et al. CCAAT-enhancer binding protein delta C/EBPdelta protects against Klebsiella pneumoniae-induced pulmonary infection: potential role for macrophage migration. J Infect Dis 2012; 206: 1826–35.
[12] Chang LH, Huang HS, Wu PT, et al. Role of macrophage CCAAT/enhancer binding protein delta in the pathogenesis of rheumatoid arthritis in collagen-induced arthritic mice. Plos ONE 2012; 7: e45378.
[13] Yan C, Johnson PF, Tang H, et al. CCAAT/enhancer-binding protein delta is a critical mediator of lipopolysaccharide-induced acute lung injury. Am J Pathol 2012; 182: 420–30.
[14] Banerjee S, Xie N, Cui H, et al. MicroRNA let-7c regulates macrophage polarization. J Immunol 2013; 190: 6542–9.
[15] O’Dwyer DN, Ashley SL, Moore BB. Influences of innate immunity, autophagy, and fibroblast activation in the pathogenesis of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2016; 311: L590-601.
[16] Song E, Ouyang N, Hörbelt M, et al. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol 2000; 204: 19–28.
[17] Wynn T A. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210.
[18] Lin C, Rezaee F, Waasdorp M, et al. Protease activated receptor-1 regulates macrophage-mediated cellular senescence: a risk for idiopathic pulmonary fibrosis. Oncotarget 2015; 6: 35304-14.
[19] Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 2010; 30: 245-57.
[20] Lekkerkerker AN, Aarbiou J, van Es T, Janssen RA. Cellular players in lung fibrosis. Curr Pharm Des 2012; 18: 4093-102.
[21] Bardou O, Menou A, François C, et al. Membrane-anchored Serine Protease Matriptase Is a Trigger of Pulmonary Fibrogenesis. Am J Respir Crit Care Med 2016; 193: 847-60.
[22] Sterneck E, Paylor R, Jackson-Lewis V, et al. Selectively enhanced contextual fear conditioning in mice lacking the transcriptional regulator CCAAT/enhancer binding protein delta.Proc Natl Acad Sci USA 1998; 95: 10908-10913.
[23] Lin C, Duitman J, Daalhuisen J, et al. Targeting protease activated receptor-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis. Thorax 2014; 69: 152-160.
[24] Lin C, von der Thüsen J, Isermann B, et al. High endogenous activated protein C levels attenuates bleomycin-induced pulmonary fibrosis. J Cell Mol Med 2016; 20: 2029-2035.
[25] Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988; 41: 467-470.
[26] Hu HM, Baer M, Williams SC, et al. Redundancy of C/EBP alpha,-beta, and -delta in supporting the lipopolysaccharide-induced transcription of IL-6 and monocyte chemoattractant protein-1. JImmunol 1998; 160: 2334-2342.
[27] Lu YC, Kim I, Lye E, et al. Differential role for c-Rel and C/ EBPbeta/delta in TLR-mediated induction of proinflammatory cytokines. J Immunol 2009; 182: 7212-7221.
[28] Duitman J, Borensztajn KS, Pulskens WP, et al. CCAAT enhancer binding protein delta (C/EBPδ) attenuates tubular injury and tubulointerstitial fibrogenesis during chronic obstructive nephropathy. Lab Invest 2014; 94: 89-97.
[29] Withana NP, Ma X, McGuire HM, et al. Non-invasive Imaging of Idiopathic Pulmonary Fibrosis Using Cathepsin Protease Probes. Sci Rep 2016; 6:19755.
[30] Banerjee S, Xie N, Cui H, et al. MicroRNA let-7c regulates macrophage polarization. J Immunol 2013; 190: 6542-6549.